Ce diaporama a bien été signalé.
Nous utilisons votre profil LinkedIn et vos données d’activité pour vous proposer des publicités personnalisées et pertinentes. Vous pouvez changer vos préférences de publicités à tout moment.

New Science: Pharma's new growth machine

12 177 vues

Publié le

Biopharma is facing compressive disruption that could impact traditional approaches. Find out how New Science can reshape the biopharma landscape and patient care. Visit http://www.accenture.com/newscience to learn more.

Publié dans : Technologie

Les commentaires sont fermés

  • Soyez le premier à commenter

New Science: Pharma's new growth machine

  1. 1. NEW SCIENCE Biopharma’s New Growth Machine Accenture LifeSciences Patient Inspired. Outcomes Driven.
  2. 2. 2 The Biopharma industry is facing compressive disruption, But a new growth engine is emerging that will drive the majority of revenue through 2022. We call it New Science.
  3. 3. 3 WHAT IS COMPRESSIVE DISRUPTION? Many asset-heavy organizations are experiencing a gradual and dangerous “compressive disruption” when a series of innovations, macroeconomic factors and other changes combine to squeeze profits over time.
  4. 4. BIOPHARMA’S COMPRESSIVE DISRUPTION DECLINES IN: Three key indicators in Biopharma Investor confidence in future earnings Tenure of marketing leading treatments Pipeline replacement ratios 01 02 03
  5. 5. 5 Investor confidence in future earnings is declining. Future Value as a percentage of Total Enterprise Value has dropped for three years in a row, from 42% in 2015 to 28% in 2018. BIOPHARMA’S COMPRESSIVE DISRUPTION 01 Sources: Capital IQ. Accenture Research Analysis. Calculations are the aggregated values for the pharmaceutical segment. Accenture High Performance Business Analysis 2018. Pharmaceutical & Biotechnology relative performance analysis of indicators including, growth profitability, and value indicators as reported by the market and monitored over 10 years. The HPB study identifies which companies are top performers within their industry and what distinguished them from their international peers
  6. 6. 6 Tenure of market leading treatments is declining. Average tenure for a market leading treatment in a therapeutic area has dropped from 10.5 years in 2001 to 5.1 years in 2017. BIOPHARMA’S COMPRESSIVE DISRUPTION 02 Source: Accenture analysis, data provided by Evaluate Pharma
  7. 7. 7 BIOPHARMA’S COMPRESSIVE DISRUPTION 50% decline expected from 2012 thru 2022. More specialized treatments coming to market that treat smaller patient populations generating lower revenues. Pipeline replacement ratios are declining.03 Source: Accenture analysis, data provided by Evaluate Pharma
  8. 8. NEW SCIENCE INVOLVES: A new mechanism, modality, indication or health technology that has been identified by the FDA or other regulatory entity as having met an unmet need, exceeding standard of care Often has a technology companion Can be the technology alone WHAT IS NEW SCIENCE?
  9. 9. 9 NEW SCIENCE WILL DRIVE THE MAJORITY OF INDUSTRY GROWTH New Science is expected to drive 54% of industry revenue from 2017-2022. Source: Accenture Research. Capital IQ.
  10. 10. 10 NEW SCIENCE IS DRIVING EXCEPTIONAL GROWTHACROSS MULTIPLE THERAPEUTIC AREAS Source: Accenture analysis, data provided by Evaluate Pharma
  11. 11. 11 NEW SCIENCE IS MORE LIKELY TO REACH AND PASS REGULATORY APPROVAL New Science has a 50% higher probability of Technical and Regulatory Success (PTRS) compared to other NMEs and NBE’s. Source: Accenture analysis, data provided by Informa Pharmapremia
  12. 12. 12 LEADERS IN NEW SCIENCE ARE INVESTING 6-7 X’S AS MUCH IN DIGITAL, DATA AND GENOMICS Investments represent convergence of science and technology rising to meet demand for proof of improved outcomes. Source: Accenture analysis
  13. 13. 13 TECHNOLOGY IS FAST BECOMING PART OF TREATMENT in some cases, the entire treatment.
  14. 14. 14
  15. 15. 18 RESEARCH METHODOLOGY Accenture Research defines a segment of science as new across three dimensions. Based on a global product level analysis of 4000 unique products of a total validated data base of 60,000 unique products as updated December 15, 2018. This New Science Growth Assessment was undertaken to better understand growth/risk levers for products, companies and therapeutic areas and to define an actionable category of interest and further evaluation. Copyright © 2019 Accenture. All rights reserved.

×